Humana Inc. (NYSE:HUM – Get Free Report) insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Humana Stock Performance
Shares of HUM stock traded up $10.79 during trading hours on Friday, reaching $263.44. 566,758 shares of the company’s stock were exchanged, compared to its average volume of 707,672. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $471.37. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $31.72 billion, a P/E ratio of 23.33, a P/E/G ratio of 2.12 and a beta of 0.53. The business has a fifty day moving average price of $272.56 and a 200-day moving average price of $314.60.
Humana (NYSE:HUM – Get Free Report) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts predict that Humana Inc. will post 16.14 EPS for the current fiscal year.
Humana Dividend Announcement
Analysts Set New Price Targets
A number of equities research analysts have issued reports on HUM shares. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Jefferies Financial Group downgraded Humana from a “buy” rating to a “hold” rating and lowered their target price for the company from $519.00 to $253.00 in a research note on Monday, October 7th. Piper Sandler lowered Humana from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $392.00 to $274.00 in a report on Thursday, October 3rd. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Finally, Morgan Stanley lifted their target price on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $300.50.
Get Our Latest Analysis on HUM
Hedge Funds Weigh In On Humana
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV grew its holdings in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. bought a new position in Humana in the third quarter worth $29,000. Ashton Thomas Securities LLC acquired a new stake in Humana during the third quarter worth $31,000. Your Advocates Ltd. LLP increased its holdings in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. Finally, Hollencrest Capital Management acquired a new position in shares of Humana in the 2nd quarter valued at $40,000. 92.38% of the stock is currently owned by institutional investors.
Humana Company Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
- Five stocks we like better than Humana
- What Are Some of the Best Large-Cap Stocks to Buy?
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Want to Profit on the Downtrend? Downtrends, Explained.
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Stock Sentiment Analysis: How it Works
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.